Jump to:
Bsf Enterprise PLC Fundamentals
| Company Name | Bsf Enterprise PLC | Last Updated | 2024-04-26 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 103.337 m | Market Cap | £5.37 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.02 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0298 | Debt Equity Ratio | 0.0161 |
|---|
| Asset Equity Ratio | 1.0827 | Cash Equity Ratio | 0.4773 |
|---|
| Quick Ratio | 7.9342 | Current Ratio | 8.31 |
|---|
| Price To Book Value | 1.0102 | ROCE | 0 |
|---|
Bsf Enterprise PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Bsf Enterprise PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £252,833.00 | £297,048.00 | 0 |
| Intangible Assets | £2.49 m | £2.49 m | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £2.74 m | £2.78 m | 0 |
| Stocks | £45,811.00 | £21,855.00 | 0 |
| Debtors | £89,934.00 | £77,985.00 | 0 |
| Cash & Equivalents | £2.32 m | £1.06 m | £359,868.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £5.26 m | £4.03 m | £401,446.00 |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £303,620.00 | £278,576.00 | £36,630.00 |
| Creditors after 1 year | £98,007.00 | £170,896.00 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £401,627.00 | £449,472.00 | £36,630.00 |
| Net assets | £4.86 m | £3.58 m | £364,816.00 |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £1.03 m | £859,869.00 | £203,400.00 |
| Share Premium | £6.29 m | £3.71 m | £407,984.00 |
| Profit / Loss | -£1.58 m | -£929,432.00 | -£58,325.00 |
| Other Equity | £4.86 m | £3.58 m | £364,816.00 |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £4.86 m | £3.58 m | £364,816.00 |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | £0.02 | £0.04 | 0 |
| Debt-to-Equity | £0.02 | £0.04 | 0 |
| Assets / Equity | 1.0827 | 1.0827 | 1.0827 |
| Cash / Equity | 0.4773 | 0.4773 | 0.4773 |
| EPS | -£0.02 | -£0.02 | £-0.00 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£1.38 m | -£667,239.00 | -£85,193.00 |
| Cashflow before financing | £1.32 m | £699,911.00 | -£85,193.00 |
| Increase in Cash | £1.26 m | £701,661.00 | -£85,193.00 |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £12,942.00 | 0 | 0 |
| Cost of sales | £71,324.00 | 0 | 0 |
| Gross Profit | -£58,382.00 | 0 | 0 |
| Operating Profit | -£1.57 m | -£927,322.00 | -£58,325.00 |
| Pre-Tax profit | -£1.58 m | -£929,432.00 | -£58,325.00 |
Bsf Enterprise PLC Company Background
| Sector | Healthcare |
|---|
| Activities | BSF Enterprise PLC provides investment opportunities in the United Kingdom. Its activity is to undertake the acquisition of businesses in the biotechnology, marketing, and e-commerce sectors. |
|---|
| Latest Interim Date | 29 Jun 2023 |
|---|
| Latest Fiscal Year End Date | 31 Jan 2024 |
|---|
Bsf Enterprise PLC Directors
| Appointed | Name | Position |
|---|
| 2024-01-31 | Mr. Geoffrey Robert Baker | Non-Executive Director,Company Secretary |
| 2024-01-31 | Ms. Min Yang | Non-Executive Director,Chairman |
| 2024-01-31 | Professor Che John Connon | Executive Director,Chief Executive Officer |
Bsf Enterprise PLC Contact Details
Bsf Enterprise PLC Advisors
